Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
В России зарегистрирован препарат для лечения раннего HER2-положительного рака молочной железы
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Инструкция по медицинскому применению лекарственного препарата Кадсила®. Государственный реестр лекарственных средств. https://grls.rosminzdrav.ru/Default.aspx
[Instruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata Kadsila®. Gosudarstvennyi reestr lekarstvennykh sredstv. https://grls.rosminzdrav.ru/Default.aspx (in Russian).]
2. Von Minckwitz G et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med 2019; 380 (7): 617–28. DOI: 10.1056/NEJMoa1814017
3. Cortazar P et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014; 384 (9938): 164–72.
4. Gianni L et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet 2016; 17 (6): 791–800.
5. Scharl A et al. The Right Treatment for the Right Patient – Personalised Treatment of Breast Cancer. Geburtshilfe Frauenheilkd 2015; 75 (7): 683–91.
6. Johns Hopkins Medicine. Neoadjuvant and Adjuvant Chemotherapy. http://www.hopkinsmedicine.org/breast_center/treatments_services/medical_oncology/neoadjuvant_adjuva...
7. Slamon D et al. BCIRG 006 trial. Presented at: SABCS; 2015 Dec 6–10; San Antonio, TX, USA. Abstract #S5-04.
8. Hurvitz SA et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2013; 31 (9): 1157–63.
9. Verma S et al. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. N Engl J Med 2012; 367 (19): 1783–91.
10. US Food and Drug Administration. Breakthrough Therapy. https://www.fda.gov/ForPatients/Approvals/Fast/ucm405397.htm.
11. Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2018.
[Malignant neoplasms in Russia in 2017 (morbidity and mortality). Ed. HELL. Kaprina, V.V. Starinsky, G.V. Petrova. Moscow, 2018 (in Russian).]
12. Wolff AC et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013; 31 (31): 3997–4013.
13. Ducry L. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem 2010; 21: 5–13.
14. ADC Review. What are antibody-drug conjugates? https://adcreview.com/adc-university/adcs-101/antibody-drug-conjugates-adcs
[Instruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata Kadsila®. Gosudarstvennyi reestr lekarstvennykh sredstv. https://grls.rosminzdrav.ru/Default.aspx (in Russian).]
2. Von Minckwitz G et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med 2019; 380 (7): 617–28. DOI: 10.1056/NEJMoa1814017
3. Cortazar P et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014; 384 (9938): 164–72.
4. Gianni L et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet 2016; 17 (6): 791–800.
5. Scharl A et al. The Right Treatment for the Right Patient – Personalised Treatment of Breast Cancer. Geburtshilfe Frauenheilkd 2015; 75 (7): 683–91.
6. Johns Hopkins Medicine. Neoadjuvant and Adjuvant Chemotherapy. http://www.hopkinsmedicine.org/breast_center/treatments_services/medical_oncology/neoadjuvant_adjuva...
7. Slamon D et al. BCIRG 006 trial. Presented at: SABCS; 2015 Dec 6–10; San Antonio, TX, USA. Abstract #S5-04.
8. Hurvitz SA et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2013; 31 (9): 1157–63.
9. Verma S et al. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. N Engl J Med 2012; 367 (19): 1783–91.
10. US Food and Drug Administration. Breakthrough Therapy. https://www.fda.gov/ForPatients/Approvals/Fast/ucm405397.htm.
11. Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2018.
[Malignant neoplasms in Russia in 2017 (morbidity and mortality). Ed. HELL. Kaprina, V.V. Starinsky, G.V. Petrova. Moscow, 2018 (in Russian).]
12. Wolff AC et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013; 31 (31): 3997–4013.
13. Ducry L. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem 2010; 21: 5–13.
14. ADC Review. What are antibody-drug conjugates? https://adcreview.com/adc-university/adcs-101/antibody-drug-conjugates-adcs
________________________________________________
1. Instruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata Kadsila®. Gosudarstvennyi reestr lekarstvennykh sredstv. https://grls.rosminzdrav.ru/Default.aspx (in Russian).
2. Von Minckwitz G et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med 2019; 380 (7): 617–28. DOI: 10.1056/NEJMoa1814017
3. Cortazar P et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014; 384 (9938): 164–72.
4. Gianni L et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet 2016; 17 (6): 791–800.
5. Scharl A et al. The Right Treatment for the Right Patient – Personalised Treatment of Breast Cancer. Geburtshilfe Frauenheilkd 2015; 75 (7): 683–91.
6. Johns Hopkins Medicine. Neoadjuvant and Adjuvant Chemotherapy. http://www.hopkinsmedicine.org/breast_center/treatments_services/medical_oncology/neoadjuvant_adjuva...
7. Slamon D et al. BCIRG 006 trial. Presented at: SABCS; 2015 Dec 6–10; San Antonio, TX, USA. Abstract #S5-04.
8. Hurvitz SA et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2013; 31 (9): 1157–63.
9. Verma S et al. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. N Engl J Med 2012; 367 (19): 1783–91.
10. US Food and Drug Administration. Breakthrough Therapy. https://www.fda.gov/ForPatients/Approvals/Fast/ucm405397.htm.
11. Malignant neoplasms in Russia in 2017 (morbidity and mortality). Ed. HELL. Kaprina, V.V. Starinsky, G.V. Petrova. Moscow, 2018 (in Russian).
12. Wolff AC et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013; 31 (31): 3997–4013.
13. Ducry L. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem 2010; 21: 5–13.
14. ADC Review. What are antibody-drug conjugates? https://adcreview.com/adc-university/adcs-101/antibody-drug-conjugates-adcs
Авторы
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.